A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Rational design of a booster vaccine against COVID-19 based on antigenic distance
The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002–2021): a population-based study
Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study
Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
Symptomatic Pneumonitis with Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer
Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies
Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522
Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50%
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)
